Any links to third-party websites or content are provided merely as a convenience and Helius makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any such information. The inclusion of any third-party link or content on the Site does not imply an endorsement or recommendation by Helius or any relationship between Helius and any third party. Your use of any such third-party content, site, or platform is at your own risk and will be governed by such third-party’s terms and policies.
Kevin Byrne shares his experience with MS and PoNS Therapy.
Neuro Rehab Times speaks to Helius’ chief medical officer, Dr. Antonella Favit-VanPelt, MD, PhD, about PoNS Therapy® and the PoNSTEP study results.
Helius Medical Technologies Inc. has surpassed initial enrollment targets for its stroke registrational program evaluating PoNS Therapy, a novel neuromodulation approach to improve gait and balance in stroke patients, aiming for FDA authorization in 2025.
In this article, the results of the new real-world PoNSTEP study are highlighted, most notably that sustained improvements in gait are linked to strict adherence to the 14-week PoNS Therapy regimen.
Recently announced data from the PoNSTEP trial showed that treatment with Helius’ Portable Neuromodulation Stimulator (PoNS), a non-implantable, orally applied therapy, resulted in improved gait deficit among patients with multiple sclerosis (MS).
In this podcast episode, US Army veteran Kevin Byrne details his unstoppable fight against MS, from the first tingles in his limbs, to philanthropic work done through his non-profit organization “Never Stop Never Quit”, where he offers insight to fellow MS patients on how to live their best MS life.
In this spotlight feature, Army Veteran & PoNS user, Kevin Byrne, discusses his battle with MS, and how PoNS helped him Get Back In Step With Life.
Antonella Favit-Van Pelt, MD, PhD, chief medical officer at Helius Medical Technologies, gave perspective on the clinical advantages of the company’s non-implantable device to treat gait in multiple sclerosis, in this interview from Neurology Live.
In this interview, Dr. Antonella Favit-VanPelt, a distinguished neurologist and chief medical officer at Helius Medical Technologies, discusses her lifelong passion for understanding the ‘why’ behind sickness, ignited by her childhood curiosity.
Join Helius at this year’s CSM in Boston, MA, and learn more about PoNS Therapy.
Note: The device has been authorized in Australia as a non-implantable neurostimulator intended for short-term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. It is not yet commercially available in Australia.
Listen to PoNS’ recent appearance on The MSing Link podcast hosted by Dr. Gretchen Hawley. In this episode, Dr. Hawley interviews Whitney Patrickson Director of PT at Helius Medical, and Dr. Naseem Chatiwala.
Individual results and patient experiences vary.
Speak to your physician to determine if PoNS is right for you.
Read Dr. Naseem Chatiwala’s article about PoNS, a portable therapy that improves gait for people with multiple sclerosis (MS), and how it pushes physical therapy beyond the plateau many patients and physical therapists experience in progress.
A first-of-its-kind technology is boosting the benefit of physical therapy for MS patients through electrical pulses that aim to ‘rewire’ the brain and activate neural pathways.
Shepherd Center has joined Helius Medical Technologies, Inc.’s Therapeutic Experience Program (TEP).
Neurological wellness company Helius Medical Technologies launched its breakthrough Portable Neuromodulation Stimulator (PoNS) to help multiple sclerosis (MS) patients who struggle to walk.
